Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-28
1996-08-20
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514471, A61K 31425, A61K 3134
Patent
active
055479693
ABSTRACT:
The neuropsychiatric symptom of bradyphrenia in a Parkinson's Disease patient may be ameliorated by treating the patient with a histamine H.sub.2 -antagonist that passes the blood brain barrier. Suitable H.sub.2 -antagonists include famotidine and ranitidine. The H.sub.2 -antagonists may be co-administered with other compounds such as histamine H.sub.1 -antagonists which are known to be useful in the treatment of Parkinson's Disease, and can be formulated with such other compounds into a therapeutic composition.
REFERENCES:
patent: 4757060 (1986-04-01), Lukacsko et al.
patent: 4806548 (1989-02-01), Ivanova et al.
patent: 5070101 (1991-12-01), Kaminski
patent: 5177081 (1993-01-01), Kaminski
patent: 5352688 (1994-10-01), Kaminski
Cahill et al, Chemical Abstracts, vol. 104, No. 19, May 1986, Abstract 167c, p. 481.
Kaminski et al., 1990, The Lancet, 335:1351-1352.
Alan J. Gelenberg, M.D., 1990, Biological Therapies in Psychiatry Newsletter vol. 13, No. 11.
Drug Information for the Health Care Professional, 1990, USP DI 1990 10th Anniversary Edition, pp. 1495-1505.
Joseph R. Bianchine, 1985, MacMillan Publishing Company, Goodman and Gilman's The Pharmacological Basis of Therapeutics, Seventh Edition, 21:472-486.
Growdon et al., 1990, Advances in Neurology 53:365-37, Parkinson's Disease: Anatomy, Pathology, and Therapy.
Danilczyk et al., 1990, Advances in Neurology 53:405-410, Parkinson's Disease: Anatomy, Pathology and Therapy.
Calne et al., 1990, Advances in Neurology, Parkinson's Disease: Anatomy, Pathology and Therapy, 53:355-360.
Y. Agid et al., 1990, Advances in Neurology 53:83-100, Parkinson's Disease: Anatomy, Pathology and Therapy.
J. L. Cummings, M.D., 1992, Am. J. Psychiatry 149:4, 443-454.
M. Garbarg et al., 1983, The Lancet, 74-75.
M. H. Coelho et al., 1991, Molecular and Chemical Neuropathology 14:77-85.
J. Poirier et al., 1987, The Lancet p. 386.
S. Nakamura and S. Vincent, 1986, Neuroscience Letters 65:321-325.
Cumming et al., 1989, European Journal of Pharmacology 166:299-301.
U. Knigge and J. Warberg, 1991, Acta Endocrinologica (Copenh) 124:609-619.
Cumming et al., 1990, European Journal of Pharmacology 184:299-301.
Oishi et al., 1990, European Journal of Pharmacology 184:135-142.
Cumming et al., 1991, SYNAPSE 8 pp. 144-151.
S. Chiavegatto et al., 1991, Pharmacology Biochemistry & Behavior 140:191-193.
Matzen et al., 1990, Neuroendocrinology 52:175-180.
Sakai et al., 1991, Life Sciences 48:2397-2404.
Onodera er al., 1991, Birkhauser Verlag, Basel, Agents and Actions 33:143-146.
U. P. Knigge, 1990, Danish Medical Bulletin vol. 37, No. 2:109-124.
A. Eisen and D. Calne, 1992, Can. J. Neurol. Sci 19:117-120.
Dooneief, M.D. et al., 1992, Arch Neurol, 49:305-307.
M. H. Sharpe, 1992, Neuropsychologia vol. 30, No. 1:101-106.
Berkow et al., 1981, "The Merck Manual of Diagnosis and Therapy", 14th Edition, published by Merck, Sharp & Sohne Research Laboratories, pp. 1359-1362 and 2336-2337.
Cintins Marianne M.
Jarvis William R. A.
Mount Sinai School of Medicine of the City University of New Yor
LandOfFree
Method for the treatment of bradyphrenia in Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of bradyphrenia in Parkinson's disease , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of bradyphrenia in Parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2330991